Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs

Format: Webinar
Credit(s): 1.00 (60 min)
Webinar Date(s):
December 7, 2022 5:15 PM - 6:15 PM CT
December 8, 2022 6:00 PM - 7:00 PM CT
Credit Type(s):
  • MIPS Improvement Activity Under MACRA
  • Physicians – AMA PRA Category 1 Credit(s) ™
  • Physicians/ABIM MOC – ABIM MOC Point(s)

PROGRAM OVERVIEW

Anemia in CKD is associated with poor CV outcomes, increased risk of CKD progression, decreased health-related quality of life (HRQOL), and increased healthcare resource utilization. Erythropoiesis-stimulating agents have been the standard of care for treating anemia in CKD but are associated with CV safety concerns; other therapies include red blood cell transfusions and iron administration but each potentially has severe adverse events.

Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are promising novel agents in development for treating CKD-associated anemia. These oral agents increase endogenous erythropoietin production, improve iron absorption and mobilization, and decrease hepcidin production in the liver.

Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs will provide cardiologists with information about the etiology of anemia in CKD, the effects on CV disease, HRQOL, and function, advantages and limitations of current management strategies, and the efficacy and safety data for HIF-PHIs in late-stage development for the management of CKD-related anemia.

PROVIDER

Jointly provided by USFH and Rockpointe

     
This educational activity is supported by an educational grant from GlaxoSmithKline.

RELATED COURSES

A Breath of Fresh Air: New Treatment Strategies for Chronic Rhinosinusitis with Nasal Polyps

Learn More

Lowering the Burden of Anemia in CKD: Looking to the Future with HIF-PHIs

Learn More

Integrating the FDA Mycophenolate Safety Standards to Prevent Adverse Pregnancy Outcomes

Learn More
This entry was posted in . Bookmark the permalink.

Follow Us :

Follow Us :

© 2021 Rockpointe Corporation

Privacy Policy

© 2021 Rockpointe Corporation

Privacy Policy